Nuclear Medicine

FDG stands for Fluorodeoxyglucose and it is a positron-emitting radiotracer used with positron emission tomography (PET) to diagnose cancer and monitor various conditions. Metabolic imaging using FDG PETCT has become the cornerstone of oncologic imaging and has been shown to be useful in tumor staging and follow-up.

FDG PETCT has also proven useful in predicting prognosis and treatment response. In certain diseases, such as lymphoma, higher FDG uptake is an indication of a higher-grade malignancy.

It is the most accurate, non-invasive imaging modality to differentiate between a benign and malignant tumour, sparing patients the painful diagnostic surgeries and suggesting treatment options earlier in the course of the disease.

A combination of PET examinations with FDG and C11-Acetate is shown to have an incremental value when compared to single tracer-imaging in the diagnosis for liver cancer.

F18-Fluoromethylcholine (FCH) has proven to be superior to FDG in the detection of metastatic disease, including that of extensive bone metastases from prostate cancer.

PET Imaging with 68Ga-PSMA can present lesions suspicious for prostate cancer with excellent contrast and a high detection rate even when the level of prostate specific antigen is low.

It is a more superior tracer compared to F-18 Choline.

It allows the identifications of benign and malignant prostatic epithelium and may be a potentially valuable marker in the treatment of patients with prostate cancer.

This scan is done to diagnose neuroendocrine tumours, which involve both the nervous system and the endocrine glands.

PET imaging using Gallium-68 (Ga-68) labelled compound -DOTATATE offers higher resolution and improved pharmacokinetics compared with somatostatin receptor scintigraphy, with promising results in the detection of SST receptor-expressing tumours.

The PETCT scanner detects where the tumours have absorbed the Gallium and shows them as a bright patches on the images.

NaF18-PETCT is used to find out if cancer has spread to the bone. Sodium Fluoride PET/CT bone scan has greater sensitivity, the higher photon flux with NaF-18 makes the lesions more conspicuous and easier to see.

This translates to detection of relatively higher number of lesions on PET bone scan.

Breakthroughs in imaging and Diagnostics technology now make it possible for early detection of Alzheimer’s Disease.

RadLink has offered Alzheimer’s disease assessment with Vizamyl™, an amyloid positron-emission tomography (PET) scanning for patients with memory complaints. Amyloid PET scan, enable early detection of amyloid in patients suspected of pre-dementia, providing a more precise understanding of the changes going on in their brains.